nex-Zol Pharma
Developer of locally-enhanced topical transdermal formulations focused on improving skin penetration, tissue retention, and sustained (time-release) delivery. Publishes comparative permeation data and seeks development partners and investors to advance formulation development.
Industries
Nr. of Employees
small (1-50)
nex-Zol Pharma
San Clemente, California, United States, North America
Products
Locally-enhanced topical transdermal formulation (prototype)
A topical formulation designed for enhanced skin penetration, increased tissue retention, and time-released delivery; sample data shows higher permeation and flux versus comparator formulations.
Nex-Zol Formulation
A novel locally enhanced transdermal delivery formulation of diclofenac gel that exhibits superior skin permeation and a time-released effect compared to leading competition.
Locally-enhanced topical transdermal formulation (prototype)
A topical formulation designed for enhanced skin penetration, increased tissue retention, and time-released delivery; sample data shows higher permeation and flux versus comparator formulations.
Nex-Zol Formulation
A novel locally enhanced transdermal delivery formulation of diclofenac gel that exhibits superior skin permeation and a time-released effect compared to leading competition.
Services
Facilitation of funding and collaborative development relationships with investors and external partners.
Facilitation of funding and collaborative development relationships with investors and external partners.
Expertise Areas
- Topical and transdermal formulation development
- Skin permeation and delivery evaluation
- Formulation performance benchmarking
- Sustained-release topical delivery
Key Technologies
- Locally-enhanced transdermal formulations
- In vitro skin permeation testing
- Flux/permeation rate analysis
- Sustained-release topical delivery methods
News & Updates
Company states it is actively seeking investors and development partners and provides a contact for investor relations.
Site cites a 2017 review on skin penetration and tissue permeation after topical administration of diclofenac (Martina Hagen & Mark Baker, Current Medical Research and Opinion).
Company states it is actively seeking investors and development partners and provides a contact for investor relations.
Site cites a 2017 review on skin penetration and tissue permeation after topical administration of diclofenac (Martina Hagen & Mark Baker, Current Medical Research and Opinion).